Adenovirus-mediated p53 gene therapy for human gliomas

Neurosurgery

Volumn 45, Issue 5, 1999, Pages 1093-1104

  Lang, Frederick F ^a   Yung, W K Alfred ^a   Sawaya, Raymond ^a   Tofilon, Philip J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Gene therapy; Gliomas; P53 gene

Indexed keywords

PROTEIN P53;

ADENOVIRUS; CANCER THERAPY; GENE THERAPY; GENE TRANSFER; GLIOMA; HUMAN; IONIZING RADIATION; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ADENOVIRIDAE; APOPTOSIS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOMA; HUMANS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032704032     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199911000-00016     Document Type: Review

References (83)

1. Adachi J-I, Ookawa K, Kohno T, Tomizawa Y, Tsuchida S, Yokota J: Phenotypic alterations of small cell lung carcinoma induced by different levels of wild-type p53 expression. Cell Death Differ 5:148-155, 1998.
2. Albertoni M, Daub DM, Arden KC, Viars CS, Powell C, Van Meir EG: Genetic instability leads to loss of both p53 alleles in a human glioblastoma. Oncogene 16:321-326, 1998.
3. Anderson WF: Human gene therapy. Nature 392[Suppl]:25-30, 1998.
4. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL: Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol Res 17:209-216, 1995.
5. Badie B, Hunt K, Economou JS, Black KL: Stereotactic delivery of a recombinant adenovirus into a C6 glioma cell line in a rat brain rumor model. Neurosurgery 35:910-916, 1994.
6. Badie B, Kramar MH, Lau R, Boothman DA, Economou JS, Black KL: Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. J Neurooncol 37:217-222, 1998.
7. Beaudry GA, Bertelsen AH, Sherman MI: Therapeutic targeting of the p53 tumor suppressor gene. Curr Opin Biotechnol 7:592-600, 1996.
8. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 94:303-309, 1997.
9. Blagosklonny MV, El-Deiry WS: Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75:933-940, 1998.
10. Bögler O, Huang H-JS, Cavenee WK: Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res 55:2746-2751, 1995.
11. Bögler O, Huang H-JS, Kleihues P, Cavenee WK: The p53 gene and its role in human brain tumors. Glia 15:308-327, 1995.
12. Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, Grimm EA, Roth JA: Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther 5:189-195, 1998.
13. Bruner JM, Saya H, Moser RP: Immunocytochemical detection of p53 in human gliomas. Mod Pathol 4:671-673, 1991.
14. Byrnes AP, MacLaren RE, Charlton HM: Immunological instability of persistent adenovirus vectors in the brain: Peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci 16:3045-3055, 1996.
15. Canman CE, Kastan MB: Induction of apoptosis by tumor suppressor genes and oncogenes. Semin Cancer Biol 6:17-25, 1995.
16. Cavenee WK: Accumulation of genetic defects during astrocytoma progression. Cancer 70[Suppl]:1788-1793, 1992.
17. Chen X, Ko LJ, Jayaraman L, Prives C: p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438-2451, 1996.
18. Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hettlich C, Freiman R, Hedley-Whyte ET, Martuza R: TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosomes Cancer 3:323-331, 1991.
19. De Benedetti V, Bennett WP, Greenblatt MS, Harris CC: p53 tumor suppressor gene: Implications for iatrogenic cancer and cancer therapy. Med Pediatr Oncol 1[Suppl]:2-11, 1996.
20. Dorigo O, Turla ST, Lebedeva S, Gjerset RA: Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg 88:535-540, 1998.
21. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
22. Fan E, Levin DB, Glickman BW, Logan DM: Limitations in use of SSCP analysis. Mutat Res 288:85-92, 1993.
23. Frankel RH, Bayona W, Koslow M, Newcomb EW: p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency. Cancer Res 52:1427-1433, 1992.
24. Gallardo D, Drazan KE, McBride WH: Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 56:4891-4893, 1996.
25. Ginsberg D, Mechta F, Yaniv M, Oren M: Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A 88:9979-9983, 1991.
26. Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ: Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14:275-285, 1995.
27. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WK: Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89:1036-1044, 1997.
28. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56:694-699, 1996.
29. Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B, Stanbridge EJ: Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 12:1387-1395, 1992.
30. 1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys 36:95-103, 1996.
31. Harris CC: Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455, 1996.
32. Kastan MB, Canman CE, Leonard CJ: p53, cell cycle control and apoptosis: Implications for cancer. Cancer Metastasis Rev 14:3-15, 1995.
33. Kleihues P, Ohgaki H: Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol 7:1131-1136, 1997.
34. Kleihues P, Schäuble B, zur Hausen A, Estève J, Ohgaki H: Tumors associated with p53 germline mutations: A synopsis of 91 families. Am J Pathol 150:1-13, 1997.
35. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 10:1054-1072, 1996.
36. Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KN, Gregory RJ, Shepard HM, Westphal M, Maneval DC: Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 67:808-815, 1996.
37. Kyritsis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS, Levin VA, Saya H: Germline p53 gene mutations in a subset of glioma patients. J Natl Cancer Inst 86:344-349, 1994.
38. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. MoI Carcinog 15:1-4, 1996.
39. Lamb P, Crawford L: Characterization of the human p53 gene. Mol Cell Biol 6:1379-1385, 1986.
40. Lane DP: p53, guardian of the genome. Nature 358:15-16, 1992.
41. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW: High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 9:949-954, 1994.
42. Lang FL, Yung WKA, Raju U, Libunao F, Terry NHA, Tofilon PJ: Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J Neurosurg 89:125-132, 1998.
43. Lee Y, Chen Y, Chang L-S, Johnson LF: Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. Exp Cell Res 234:270-276, 1997.
44. Leenstra S, Troost D, Westerveld A, Bosch DA, Hulsebos TJM: Molecular characterization of areas with low grade tumor or satellitosis in human malignant astrocytomas. Cancer Res 52: 1568-1572, 1992.
45. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991.
46. Li H, Alonso-Vanegas M, Colicos MA, Jung SS, Lochmuller H, Sadikot AF, Snipes GJ, Seth P, Karpati G, Nalbantoglu J: Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clin Cancer Res 5:637-642, 1999.
47. Deleted in proof.
48. Louis DN, von Deimling A, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD, Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52:31-38, 1993.
49. Lubbe J, von Ammon K, Watanabe K, Hegi ME, Kleihues P: Familial brain tumour syndrome associated with a p53 germline deletion of codon 236. Brain Pathol 5:15-23, 1995.
50. Malkin D: p53 and the Li-Fraumeni syndrome. Biochim Biophys Acta 1198:197-213, 1994.
51. Deleted in proof.
52. Matsumoto M, Tsuchida T, Kawamoto K: Cisplatin-induced cell death in human glioma: Apoptosis or necrosis? Int J Oncol 11: 1209-1212, 1997.
53. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ: Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A 87:6166-6170, 1990.
54. Meyn RE, Stephens LC, Ang KK, Hunter NR, Brock WA, Milas L, Peters LJ: Heterogeneity in apoptosis development in irradiated murine tumors. Int J Radiat Biol 64:583-591, 1993.
55. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
56. Neubauer A, Thiede C, Huhn D, Wittig B: p53 and induction of apoptosis as a target for anticancer therapy. Leukemia 10[Suppl 3]:S2-S4, 1996.
57. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA: Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112:1372-1377, 1996.
58. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
59. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992.
60. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG, Fine HA: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3:1145-1149, 1997.
61. Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA: Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol 4:194-203, 1998.
62. Pellegata NS, Ranzani GN: The significance of p53 mutations in human cancers. Eur J Histochem 40:273-282, 1996.
63. Peltékian E, Parrish E, Bouchard C, Peschanski M, Lisovoski F: Adenovirus-mediated gene transfer to the brain: Methodological assessment. J Neurosci Methods 71:77-84, 1997.
64. Prives C, Hall PA: The p53 pathway. J Pathol 187:112-126, 1999.
65. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736-2739, 1993.
66. Sehgal A: Molecular changes during the genesis of human gliomas. Semin Surg Oncol 14:3-12, 1998.
67. wild-type cancer cells treated with ionizing radiation. Int J Cancer 73:757-762, 1997.
68. Shine HD, Wyde PR, Aguilar-Cordova E, Chen S-H, Woo SLC, Grossman RG, Goodman JC: Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). Gene Ther 4:275-279, 1997.
69. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavenee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846-847, 1992.
70. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2:1665-1671, 1996.
71. Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R, Minna JD: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340-2343, 1992.
72. van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang H-J, Friedmann T, de Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54:649-652, 1994.
73. Velculescu VE, El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42:858-868, 1996.
74. Venter DJ, Thomas DGT: Multiple sequential molecular abnormalities in the evolution of human gliomas. Br J Cancer 63:753-757, 1991.
75. Vogelbaum MA, Tong JX, Higashikubo R, Gutmann DH, Rich KM: Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. J Neurosurg 88:99-105, 1998.
76. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL, Schoenfeld DA, Yaşargil MG, Wiestler OD, Seizinger BR: Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 77:295-301, 1992.
77. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3:19-26, 1993.
78. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980.
79. Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: The national survey of intracranial neoplasms. Neurology 35:219-226, 1985.
80. Wang T-H, Wang H-S: p53, apoptosis and human cancers. J Formos Med Assoc 95:509-522, 1996.
81. Wood MJA, Charlton HM, Wood KJ, Kajiwara K, Byrnes AP: Immune responses to adenovirus vectors in the nervous system. Trends Neurosci 19:497-501, 1996.
82. Wu JK, Ye Z, Darras BT: Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations. Am J Hum Genet 52: 1273-1275, 1993.
83. Yount GL, Haas-Kogan DA, Vidair CA, Haas M, Dewey WC, Israel MA: Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res 56:500-506, 1996.